Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 12/20 | 0.54 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.48 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38659301 | 0.91 | BACE1 (0.63) | BACE1BACE2PTPN1CTSD | |
| SCHEMBL38657805 | 0.90 | BACE1 (0.57) | BACE1BACE2CTSD | |
| SCHEMBL30799642 | 0.90 | BACE1 (0.61) | BACE1BACE2PTPN1CTSD | |
| SCHEMBL30799436 | 0.90 | BACE1 (0.58) | BACE1BACE2PTPN1CTSD | |
| SCHEMBL29679577 | 0.90 | BACE1 (0.63) | BACE1BACE2CTSD | |
| SCHEMBL30974118 | 0.89 | BACE1 (0.62) | BACE1BACE2PTPN1CTSD | |
| SCHEMBL31181273 | 0.89 | BACE1 (0.54) | BACE1BACE2PTPN1 | |
| SCHEMBL29531643 | 0.89 | OPRD1 (0.56) | BACE1BACE2 | |
| SCHEMBL29531229 | 0.89 | OPRD1 (0.56) | BACE1BACE2 | |
| SCHEMBL30799386 | 0.89 | BACE1 (0.63) | BACE1BACE2PTPN1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120058845-A | Fatty acid modified antioxidant peptide and application thereof | 青岛双元泰和药业有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-119954971-A | Hybrid peptide GK-40 based on pig-derived antibacterial peptide PMAP-36 and antibacterial peptide CRAMP and application thereof | 西南大学 | 2025-05-09 | — | — | CN | claimed |
| CN-119912579-A | Chimeric antigen receptor immune cell constructed based on cyclopeptide Peptide G and application thereof | 四川大学华西医院 | 2025-05-02 | — | — | CN | claimed |
| CN-119524018-A | Method for promoting growth of natural bezoar by using novel small molecular peptide combination | 北京永慧互赢科技有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-119095622-A | NMDAR antagonists prevent aging and aging-related conditions and diseases by increasing 20S proteasome activity | 菲克雷特·萨欣 | 2024-12-06 | — | — | CN | claimed |
| CN-118806879-A | Composition with bone joint health care function and application thereof | 云南省药物研究所 | 2024-10-22 | — | — | CN | claimed |
| CN-114044808-B | Albumin affinity agent and application thereof | 郑州大学 | 2024-01-30 | — | — | CN | claimed |
| US-11866736-B2 | Protein prostheses for mitochondrial diseases or conditions | THE GENERAL HOSPITAL CORPORATION (US) | 2024-01-09 | — | — | US | claimed |
| EP-3526244-B1 | PEPTIDES DERIVED FROM THE PROPEPTIDE NTSR3 AND THEIR USE IN THE TREATMENT OF DEPRESSION | CENTRE NAT RECH SCIENT (FR) | 2023-09-06 | — | — | EP | claimed |
| CN-116496376-A | Immunomodulatory peptide Og-CATH and application thereof | 昆明医科大学 | 2023-07-28 | — | — | CN | claimed |
| CN-116478860-A | Riemerella anatipestifer type 2 culture medium with high antigen activity, and preparation method and application thereof | 广东环凯生物科技有限公司 | 2023-07-25 | — | — | CN | claimed |
| CN-114891068-B | Antibacterial peptide GK18 and application thereof | 南方海洋科学与工程广东省实验室(广州) | 2023-06-16 | — | — | CN | claimed |
| CN-114891068-A | Antibacterial peptide GK18 and application thereof | 南方海洋科学与工程广东省实验室(广州) | 2022-08-12 | — | — | CN | claimed |
| US-12617865-B2 | Activated antibodies targeting PSMA and effector cell antigens | Janux Therapeutics, Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12578345-B2 | Single molecule peptide sequencing | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-17 | — | — | US | disclosed |
| US-12577589-B2 | Vaccines and uses thereof to induce an immune response to SARS-CoV2 | GEOVAX, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| WO-2022049154-A1 | HYDROGELS FOR CELL CULTURE | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-03-10 | — | — | WO | disclosed |
| US-11268120-B2 | Identification of transglutaminase substrates and uses therefor | Roche Sequencing Solutions, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3693000-B1 | PROCOAGULANT COMPOUNDS | BIOVERATIV THERAPEUTICS INC (US) | 2022-03-02 | — | — | EP | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11268120-B2 | Identification of transglutaminase substrates and uses therefor | GARS1, GGH, TGM2 | BACE1 2218/4885BACE2 1740/4885PTPN1 3587/4885 |
| US-12578345-B2 | Single molecule peptide sequencing | SET, PTMS, MICA | BACE1 1162/4885BACE2 1646/4885PTPN1 763/4885 |
| US-12577589-B2 | Vaccines and uses thereof to induce an immune response to SARS-CoV2 | STING1, EIF2AK2, IRF2BP2 | BACE1 2680/4885BACE2 633/4885PTPN1 3741/4885 |
| US-12617865-B2 | Activated antibodies targeting PSMA and effector cell antigens | CD4, PSMA1, KLK3 | BACE1 870/4885BACE2 732/4885PTPN1 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.